Subscribe

Articles

Biomarker Testing for Non–Small-Cell Lung Cancer Increased Over Time
Lung Cancer
Web Exclusives
Biomarker testing is the standard of care in advanced non–small-cell lung cancer, but the rate of patients receiving test results prior to initiating treatment is low. Read More ›
Actionable Alterations in NSCLC Detected at Varying Frequencies Across Racial Groups
Lung Cancer
Web Exclusives
Study finds that frequencies of mutations commonly found in patients with non–small-cell lung cancer vary among members of 3 racial groups. Read More ›
Patients with Lung Cancer Harboring KRAS G12C Mutation and Higher PD-L1 Expression Benefit from Immunotherapy
Lung Cancer
Web Exclusives
Study of patients with lung adenocarcinoma found that patients with KRAS G12C mutation and high PD-L1 expression benefit more from immunotherapy compared with patients with other KRAS mutations. Read More ›
Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors
Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors
By Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP; Aung Naing, MD, FACP
Supplements
Read More ›
Adagrasib Demonstrates CNS Penetration and Intracranial Activity in Patients with KRAS G12C-Mutated NSCLC with Brain Metastases
Lung Cancer
Web Exclusives
A study in patients with KRAS G12C-mutated non–small-cell lung cancer with brain metastases found adagrasib to demonstrate intracranial activity while being well tolerated. Read More ›
Postoperative ctDNA Prognostic Marker for Disease Recurrence in Patients with NSCLC
Lung Cancer
Web Exclusives
Study finds circulating tumor DNA reveals disease recurrence before radiographic evidence in patients with non–small-cell lung cancer. Read More ›
Patients with KRAS-Mutated NSCLC Benefit from First-line Combination Therapy
Lung Cancer
Web Exclusives
Recent study showed that KRAS mutation in patients with non–small-cell lung cancer predicted superior response to first-line immunotherapy. Read More ›
Frequencies of Common NSCLC KRAS and EGFR Variants in Black and White Americans
Lung Cancer
Web Exclusives
Real-world analysis of mutations in non–small-cell lung cancer showed similar frequencies of common KRAS and EGFR variants in Black and White Americans, but higher EGFR G719S variant was seen in Black Americans. Read More ›
From The Editor October 2022
From The Editor October 2022
By Catherine Bishop, DNP, NP-C, AOCNP
From the Editor
TON - October 2022 Vol 15, No 5
In the October issue of The Oncology Nurse-APN/PA (TON), we feature a variety of articles aimed at informing and empowering nurses, navigators, and advanced practice providers who work to improve the lives of patients with cancer. Read More ›
Rutgers Cancer Institute of New Jersey: Dedicated to Improving Patient Care
Cancer Center Profile
TON - October 2022 Vol 15, No 5
As New Jersey’s only National Cancer Institute–designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey, together with RWJBarnabas Health, has a singular focus and mission—to help patients fight cancer. Read More ›

Page 34 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.